Malaria Vaccine Programme - Hill Group
I am a fourth-year D.Phil. student in the pre-erythrocytic malaria vaccine group. My research focuses on optimising Pf. TRAP antigen for a liver-stage malaria vaccine using clinically tested viral vectors and vaccination regimens in murine models. In addition, I also evaluate the combination of vaccine platforms to enhance humoral and cellular immunogenicity of pre-erythrocytic-stage malaria vaccine.
During my post-graduate career, I joined the Oxford University COVID-19 vaccine trial as part of the immunology team looking at the humoral responses induced by the ChAdOX1-nCOV-19 vaccine. In addition, I also joined the student internship at COVAX Facility, GAVI, to support the technical and vaccine policy team related to the COVID-19 vaccine.
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478